These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27131966)

  • 21. Outcomes of Sacral Neuromodulation in Patients with Prior Surgical Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse.
    Bartley JM; Ramirez V; Killinger KA; Boura JA; Gupta P; Gaines N; Gilleran JP; Peters KM
    Female Pelvic Med Reconstr Surg; 2017; 23(1):8-12. PubMed ID: 27636222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study.
    Peters KM; Carrico DJ; MacDiarmid SA; Wooldridge LS; Khan AU; McCoy CE; Franco N; Bennett JB
    Neurourol Urodyn; 2013 Jan; 32(1):24-9. PubMed ID: 22674493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective, multicenter study to evaluate performance and safety of a re-engineered temporary lead for InterStim™ therapy evaluation.
    Elterman D; Michaels J; Margolis E; Harris-Hicks J; Burgess K; Betts C; Harding C; Towers G; Hashim H; Ojo-Carons A; White A; Cannon-Smith T; Grunow N; Bittner K; Xavier K
    Neurourol Urodyn; 2022 Nov; 41(8):1731-1738. PubMed ID: 35900298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sacral nerve stimulation for voiding dysfunction: One institution's 11-year experience.
    Sutherland SE; Lavers A; Carlson A; Holtz C; Kesha J; Siegel SW
    Neurourol Urodyn; 2007; 26(1):19-28; discussion 36. PubMed ID: 17078071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective Randomized Feasibility Study Assessing the Effect of Cyclic Sacral Neuromodulation on Urinary Urge Incontinence in Women.
    Siegel S; Kreder K; Takacs E; McNamara R; Kan F
    Female Pelvic Med Reconstr Surg; 2018; 24(4):267-271. PubMed ID: 28914707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increasing patient preparedness for sacral neuromodulation improves patient reported outcomes despite leaving objective measures of success unchanged.
    Firoozi F; Gill B; Ingber MS; Moore CK; Rackley RR; Goldman HB; Vasavada SP
    J Urol; 2013 Aug; 190(2):594-7. PubMed ID: 23499745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2020 Apr; 39(4):1108-1114. PubMed ID: 32243625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
    Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
    Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific Changes in Brain Activity during Urgency in Women with Overactive Bladder after Successful Sacral Neuromodulation: A Functional Magnetic Resonance Imaging Study.
    Weissbart SJ; Bhavsar R; Rao H; Wein AJ; Detre JA; Arya LA; Smith AL
    J Urol; 2018 Aug; 200(2):382-388. PubMed ID: 29630979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term efficacy and safety of sacral nerve stimulation for fecal incontinence.
    Mellgren A; Wexner SD; Coller JA; Devroede G; Lerew DR; Madoff RD; Hull T;
    Dis Colon Rectum; 2011 Sep; 54(9):1065-75. PubMed ID: 21825885
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
    Neurourol Urodyn; 2018 Feb; 37(S2):S9-S16. PubMed ID: 29315785
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Twelve-month Durability of a Fully-implanted, Nickel-sized and Shaped Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome with Urgency Urinary Incontinence: A Single-Arm, Prospective Study.
    Gilling P; Meffan P; Kaaki B; MacDiarmid S; Lucente V; Clark M; Sen SK; English S; Sand PK
    Urology; 2021 Nov; 157():71-78. PubMed ID: 34048826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Multicenter Study Evaluating the FREquency of Use and Efficacy of a Novel Closed-Loop Wearable Tibial Neuromodulation System for Overactive Bladder and Urgency Urinary Incontinence (FREEOAB).
    Goudelocke C; Sobol J; Poulos D; Enemchukwu E; Zaslau S; Dhir R
    Urology; 2024 Jan; 183():63-69. PubMed ID: 37944596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flat Magnetic Stimulation for Urge Urinary Incontinence.
    Barba M; Cola A; Rezzan G; Costa C; Re I; Volontè S; Terzoni S; Frigerio M; Maruccia S
    Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38004048
    [No Abstract]   [Full Text] [Related]  

  • 35. Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacral neuromodulation therapy for overactive bladder patients.
    Noblett K; Benson K; Kreder K
    Neurourol Urodyn; 2017 Apr; 36(4):1136-1139. PubMed ID: 27491027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-year outcomes of the ARTISAN-SNM study with the Axonics System for the treatment of urinary urgency incontinence.
    Benson K; McCrery R; Taylor C; Padron O; Blok B; de Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman H; Lane F
    Neurourol Urodyn; 2020 Jun; 39(5):1482-1488. PubMed ID: 32339339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
    Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
    Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central inhibition of refractory overactive bladder complaints, results of an inpatient training program.
    Meijer EF; Nieuwhof-Leppink AJ; Dekker-Vasse E; de Joode-Smink GC; de Jong TP
    J Pediatr Urol; 2015 Feb; 11(1):21.e1-5. PubMed ID: 25205144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychosocial factors related to the use of InterStim® for the treatment of refractory overactive bladder.
    Levin PJ; Siddiqui NY; Wu JM; Amundsen CL
    Female Pelvic Med Reconstr Surg; 2014; 20(5):272-5. PubMed ID: 25181377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.